A Clinical Trials service for pharmaceutical customers worldwide has been launched by ELC Group, the regulatory affairs consultancy that in February 2012 opened new global headquarters in Cambridge, UK.  

The end-to-end Clinical Trials offering spans bioavailability/bioequivalence and Phase I studies; Phase II to Phase IV trials; post-marketing surveillance studies; medical writing; biostatistics and statistical programming services; clinical data management; and Good Clinical Practice audits and training.

It is designed to help customers expedite the regulatory submission process and speed time to market, ELC said. The new services are fully customisable and can be offered on a stand-alone basis or as part of the consultancy’s integrated full-service package.

ELC’s other core business segments are Regulatory Affairs Services, Medical Devices, EU Reach (Registration, Evaluation and Authorisation of Chemicals) Regulation Services, and Corporate Languages Solutions.

Besides its UK base, the consultancy has offices in the Czech Republic (Prague), India (Mumbai and Ahmedabad) and Singapore.